Expression of neurotensin and NT1 receptor in human breast cancer: A potential role in tumor progression

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6243-6249

  Souazé, Frédérique ^a   Dupouy, Sandra ^a   Viardot Foucault, Véronique ^a,b   Bruyneel, Erik ^c   Attoub, Samir ^a   Gespach, Christian ^a   Gompel, Anne ^a,b   Forgez, Patricia ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔTEL DIEU   (France)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; GELATINASE B; JMV 449; JMV449; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROTENSIN; NEUROTENSIN 1 RECEPTOR AGONIST; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEUROTENSIN; RECEPTORS, NEUROTENSIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 33745700192     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0450     Document Type: Article

References (49)

1. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005;34:405-12.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
4. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-7.
5. Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 2005;23:391-409.
6. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37.
7. LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer 2002;100:2-8.
8. Pierce KL, Luttrell LM, Lefkowitz RJ. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 2001;20:1532-9.
9. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001;22:368-76.
10. Rozengurt E. Neuropeptides as growth factors for normal and cancerous cells. Trends Endocrinol Metab 2002;13:128-34.
11. Thomas RP, Hellmich MR, Townsend CM, Jr., Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev 2003;24:571-99.
12. Somai S, Gompel A, Rostene W, Forgez P. Neurotensin counteracts apoptosis in breast cancer cells. Biochem Biophys Res Commun 2002;295:482-8.
13. Souaze F, Viardot-Foucault V, Roullet N, et al. Neurotensin receptor 1 gene activation by the Tcf/β-catenin pathway is an early event in human colonic adenomas. Carcinogenesis 2006;27:708-16.
14. Tyler-McMahon BM, Boules M, Richelson E. Neurotensin: peptide for the next millennium. Regul Pept 2000;93:125-36.
15. Gully D, Canton M, Boigegrain R, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U S A 1993;90:65-9.
16. Reinecke M. Neurotensin. Immunohistochemical localization in central and peripheral nervous system and in endocrine cells and its functional role as neurotransmitter and endocrine hormone. Prog Histochem Cytochem 1985;16:1-172.
17. Gullo L, Pezzilli R, Tomassetti P, de Giorgio R. Plasma cholecystokinin and neurotensin after an ordinary meal in humans. A prolonged time study717. Gastroenterol Clin Biol 1998;22:25-8.
18. Baca I, Feurle GE, Schwab A, Mittmann U, Knauf W, Lehnert T. Effect of neurotensin on exocrine pancreatic secretion in dogs. Digestion 1982;23:174-83.
19. Andersson S, Rosell S, Hjelmquist U, Chang D, Folkers K. Inhibition of gastric and intestinal motor activity in dogs by (Gln4) neurotensin. Acta Physiol Scand 1977;100:231-5.
20. Armstrong MJ, Parker MC, Ferris CF, Leeman SE. Neurotensin stimulates [3H]oleic acid translocation across rat small intestine. Am J Physiol 1986;251:G823-9.
21. Elek J, Pinzon W, Park KH, Narayanan R. Relevant genomics of neurotensin receptor in cancer. Anticancer Res 2000;20:53-8.
22. Wang L, Friess H, Zhu Z, et al. Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin Cancer Res 2000;6:566-71.
23. Zhao D, Kuhnt-Moore S, Zeng H, Wu JS, Moyer MP, Pothoulakis C. Neurotensin stimulates IL-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-κB pathways. Am J Physiol Cell Physiol 2003;284:C1397-404.
24. Leyton J, Garcia-Marin L, Jensen RT, Moody TW. Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells. Eur J Pharmacol 2002;442:179-86.
25. Ehlers RA, Zhang Y, Hellmich MR, Evers BM. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun 2000;269:704-8.
26. Hassan S, Dobner PR, Carraway RE. Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells. Regul Pept 2004;120:155-66.
27. Zhao D, Zhan Y, Koon HW, et al. Metalloproteinase-dependent transforming growth factor-α release mediates neurotensin-stimulated MAP kinase activation in human colonic epithelial cells. J Biol Chem 2004;279:43547-54.
28. Gompel A, Malet C, Spritzer P, Lalardrie JP, Kuttenn F, Mauvais-Jarvis P. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63:1174-80.
29. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;3:359-77.
30. Souaze F, Rostene W, Forgez P. Neurotensin agonist induces differential regulation of neurotensin receptor mRNA. Identification of distinct transcriptional and post-transcriptional mechanisms. J Biol Chem 1997;272:10087-94.
31. Bracke M, Boterberg T, Bruyneel E, Mareel M. Collagen invasion assay. In: Cancer invasion and metastasis. Totowa (NJ): Humana Press; 2000. p. 81-9.
32. Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano K. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 1997;77:345-55.
33. Scorilas A, Karameris A, Arnogiannaki N, et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001;84:1488-96.
34. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002;52:255-64.
35. Levin JI, Chen JM, Du MT, et al. The discovery of anthranilic acid-based MMP inhibitors. Part 3. Incorporation of basic amines. Bioorg Med Chem Lett 2001;11:2975-8.
36. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther 2004;3:36-41.
37. Toy-Miou-Leong M, Cortes CL, Beaudet A, Rostene W, Forgez P. Receptor trafficking via the perinuclear recycling compartment accompanied by cell division is necessary for permanent neurotensin cell sensitization and leads to chronic mitogen-activated protein kinase activation. J Biol Chem 2004;279:12636-46.
38. Evers BM, Zhou Z, Dohlen V, Rajaraman S, Thompson JC, Townsend CM, Jr. Fetal and neoplastic expression of the neurotensin gene in the human colon. Ann Surg 1996;223:464-70.
39. Calhoun K, Toth-Fejel S, Cheek J, Pommier R Serum peptide profiles in patients with carcinoid tumors. Am J Surg 2003;186:28-31.
40. Theodorsson-Norheim E, Oberg K, Rosell S, Bostrom H. Neurotensinlike immunoreactivity in plasma and tumor tissue from patients with endocrine tumors of the pancreas and gut Gastroenterology 1983;85:881-9.
41. Dong Z, Wang X, Evers BM. Site-specific DNA methylation contributes to neurotensin/neuromedin N expression in colon cancers. Am J Physiol Gastrointest Liver Physiol 2000;279:G1139-47.
42. Evers BM. Endocrine gene neurotensin: molecular mechanisms and a model of intestinal differentiation. World J Surg 2002;26:799-805.
43. Watters JJ, Dorsa DM. Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms. J Neurosci 1998;18:6672-80.
44. Goettler DM, Levin L, Chey WY. Postprandial levels of prolactin and gut hormones in breast cancer patients: association with stage of disease, but not dietary fat. J Natl Cancer Inst 1990;82:22-9.
45. de Lange R, Dimoudis N, Weidle UH. Identification of genes associated with enhanced metastasis of a large cell lung carcinoma cell line. Anticancer Res 2003;23:187-94.
46. Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides 2001;22:109-15.
47. Zhao D, Keates AC, Kuhnt-Moore S, Moyer MP, Kelly CP, Pothoulakis C. Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem 2001;276:44464-71.
48. Banker NA, Hellmich MR, Kim HJ, Townsend CM, Jr., Evers BM. Src-mediated activation of the human neurotensin/neuromedin N promoter. Surgery 1997;122:180-5.
49. Pellikainen JM, Ropponen KM, Kataja W, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10:7621-8.